Q1 Earnings Forecast for ICON Public Issued By William Blair

ICON Public Limited (NASDAQ:ICLR) – Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for ICON Public in a research note issued on Thursday, February 20th. William Blair analyst M. Smock forecasts that the medical research company will earn $3.45 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.38 per share. William Blair also issued estimates for ICON Public’s Q2 2026 earnings at $3.66 EPS, Q3 2026 earnings at $3.91 EPS, Q4 2026 earnings at $4.19 EPS and FY2026 earnings at $15.20 EPS.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.01. The firm had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%.

Several other equities analysts have also weighed in on ICLR. Royal Bank of Canada reissued an “outperform” rating and set a $263.00 price objective on shares of ICON Public in a report on Wednesday, January 15th. Citigroup decreased their price objective on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a report on Monday, January 6th. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 price objective (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Truist Financial dropped their price target on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Finally, Barclays reduced their price objective on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ICON Public has an average rating of “Moderate Buy” and a consensus price target of $281.00.

ICON Public Stock Performance

Shares of ICLR stock opened at $197.50 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. The firm has a market cap of $16.29 billion, a price-to-earnings ratio of 20.72, a P/E/G ratio of 1.86 and a beta of 1.19. ICON Public has a 52 week low of $181.51 and a 52 week high of $347.72. The firm’s 50-day simple moving average is $202.69 and its two-hundred day simple moving average is $242.86.

Institutional Trading of ICON Public

Large investors have recently bought and sold shares of the company. Arkadios Wealth Advisors lifted its stake in shares of ICON Public by 5.0% in the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock valued at $371,000 after purchasing an additional 62 shares during the period. First Horizon Advisors Inc. lifted its position in ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after buying an additional 151 shares during the period. Icon Wealth Advisors LLC boosted its holdings in shares of ICON Public by 861.1% during the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after buying an additional 11,840 shares in the last quarter. Foyston Gordon & Payne Inc bought a new stake in shares of ICON Public during the 3rd quarter valued at $11,672,000. Finally, GAMMA Investing LLC grew its position in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after buying an additional 169 shares during the period. 95.61% of the stock is owned by institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.